Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300251 | 0.92 | ALDH1A1 (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL24065992 | 0.92 | CA12 (0.44) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL792222 | 0.92 | SIGMAR1 (0.45) | ALDH1A1KEAP1SMN1; SMN2KDM4EGLA | |
| SCHEMBL2733378 | 0.90 | KEAP1 (0.53) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL14997478 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL18024043 | 0.90 | CHRM3 (0.40) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL684590 | 0.89 | ALDH1A1 (0.42) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL27348846 | 0.88 | CA12 (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL428435 | 0.87 | ALDH1A1 (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL20328759 | 0.87 | SMN1; SMN2 (0.39) | ALDH1A1KEAP1SMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801500-B2 | Methods for producing tertiary amine catalysts and uses of such | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801500-B2 | Methods for producing tertiary amine catalysts and uses of such | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20210121860-A1 | METHODS FOR PRODUCING TERTIARY AMINE CATALYSTS AND USES OF SUCH | HUNTSMAN PETROCHEMICAL LLC (US) | 2021-04-29 | — | — | US | disclosed |
| WO-2020057605-A2 | GLUCOSE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 凯惠科技发展(上海)有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121860-A1 | METHODS FOR PRODUCING TERTIARY AMINE CATALYSTS AND USES OF SUCH | PNMT, HNMT, TH | ALDH1A1 249/4885KEAP1 999/4885SMN1; SMN2 4146/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885KEAP1 605/4885SMN1; SMN2 4306/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885KEAP1 605/4885SMN1; SMN2 4306/4885 |
| US-11801500-B2 | Methods for producing tertiary amine catalysts and uses of such | PNMT, HNMT, TH | ALDH1A1 249/4885KEAP1 999/4885SMN1; SMN2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.